Back to search

Article

Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistance

2023-09-16

Abstract excerpt

<h4>ABSTRACT</h4> Chimeric antigen receptors (CARs) reprogram T cells to recognize and target cancer cells. Despite remarkable responses observed with CAR-T cell therapy in patients with hematological malignancies, CAR-T cell engineering still relies mostly on randomly integrating vectors, limiting the possibilities of fine-tuning T cell function. Here, we designed a CRISPR-based marker-free selection strategy to...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
8a21a7dd-ad2b-5ee3-9c61-cc7bb92fad08
DOI
10.1101/2023.09.14.557485
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Pharmacological control of CAR T cells through CRISPR-driven rapamycin resistanceDOI 10.1101/2023.09.14.557485
Select a neighboring publication to make it the new centre.